Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study

Background: Cytoreductive therapies have been the standard treatment for patients with high-risk polycythemia vera (PV) for decades. However, approximately 24% of patients treated with hydroxyurea will eventually develop resistance or intolerance to hydroxyurea and need second-line (2L) therapy. Obj...

詳細記述

書誌詳細

主要な著者:	Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Wendy Y. Cheng, Mu Cheng, Marja Nuortti, Volker Baum, Claire Harrison
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2025-07-01
シリーズ:	Therapeutic Advances in Hematology
オンライン･アクセス:	https://doi.org/10.1177/20406207251342199
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!